---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-283033"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2026-06-25T21:08:23+00:00"
generated_at: "2026-06-25T21:10:18.026277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Spero shareholders approve doubling authorized shares to 240M and 2026 equity plan

## Summary
- Authorized common shares increased from 120M to 240M via certificate of amendment filed June 23, 2026.
- 2026 Stock Incentive Plan approved; up to 12,895,866 shares may be issued under the plan.
- Directors Milind Deshpande, Ph.D. and Kathleen Tregoning reelected as Class III directors until 2029.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 99.5% votes for.
- Advisory vote on named executive officer compensation approved with ~96% of votes cast in favor.

## SEC filing metadata
- accession: 0001193125-26-283033
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2026-06-25T21:08:23+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/0001193125-26-283033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/d86736d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-283033
- JSON: https://secwatch.observer/filing/0001193125-26-283033.json
- Plain text: https://secwatch.observer/filing/0001193125-26-283033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.